Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations - Slideshow (NASDAQ:TARA) 2025-11-19

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...